A liquid biopsy is a diagnostic test using liquid biological samples. Considered non-invasive, it can be used to track cancers, heart issues, and do prenatal diagnosis.
Date: February 09, 2021 Time: 09:00am (PST), 12:00pm (EST) In this webinar we introduce quantitative amplicon sequencing (QASeq): a highly-sensitive and robust NGS-based method for the detec...
Date: November 30, 2021 Time: 11:00am (PDT), 2:00pm (EDT) In the recent years, measurable residual disease (MRD) assessment on multiple myeloma patients has gained increasing relevance. After...
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
Date: August 24, 2021 Time: 8:00am (PST), 11:00am (EST) Liver cancer is the third cause of cancer-related mortality worldwide. Most patients have chronic liver disease, which has allowed...
Date: June 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation...
Date: June 8, 2021 Time: 9:00am PDT Reducing the spread of highly infectious and deadly diseases within the population, vaccine development is crucial in saving millions of lives each year....
According to the American Cancer Society, in there were an estimated 110,070 new cases diagnosed and approximately 32,120 deaths from gynecologic cancers in the U.S. in 2018. Of the five mos...
Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. Discovery’s recently launched S...
Cell-free DNA (cfDNA) is a key analyte for liquid biopsy samples. Due to extremely low concentration and high degree of fragmentation, the extraction of cfDNA is technically challenging. Her...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker....
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Martin highlights various factors impacting molecular analysis from FFPE samples and key challenges and considerations while working with this precious yet challenging sample type. Learning...
Antibodies have become one of the most important tools in life science research, allowing the detection, quantitation, and determination of changes in proteins and other molecules with respe...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
Cancer disparities among persons of African descent are driven by both biological and nonbiological factors. There is evidence in breast cancer that psychosocial factors (environment, socioe...
Learning Objectives: 1. To provide an overview of relevant hereditary cancer syndromes 2. To encourage providers to obtain a thorough family history 3. To educate providers about available r...
Date: February 09, 2021 Time: 09:00am (PST), 12:00pm (EST) In this webinar we introduce quantitative amplicon sequencing (QASeq): a highly-sensitive and robust NGS-based method for the detec...
Date: November 30, 2021 Time: 11:00am (PDT), 2:00pm (EDT) In the recent years, measurable residual disease (MRD) assessment on multiple myeloma patients has gained increasing relevance. After...
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
Date: August 24, 2021 Time: 8:00am (PST), 11:00am (EST) Liver cancer is the third cause of cancer-related mortality worldwide. Most patients have chronic liver disease, which has allowed...
Date: June 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation...
Date: June 8, 2021 Time: 9:00am PDT Reducing the spread of highly infectious and deadly diseases within the population, vaccine development is crucial in saving millions of lives each year....
According to the American Cancer Society, in there were an estimated 110,070 new cases diagnosed and approximately 32,120 deaths from gynecologic cancers in the U.S. in 2018. Of the five mos...
Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. Discovery’s recently launched S...
Cell-free DNA (cfDNA) is a key analyte for liquid biopsy samples. Due to extremely low concentration and high degree of fragmentation, the extraction of cfDNA is technically challenging. Her...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker....
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Martin highlights various factors impacting molecular analysis from FFPE samples and key challenges and considerations while working with this precious yet challenging sample type. Learning...
Antibodies have become one of the most important tools in life science research, allowing the detection, quantitation, and determination of changes in proteins and other molecules with respe...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
Cancer disparities among persons of African descent are driven by both biological and nonbiological factors. There is evidence in breast cancer that psychosocial factors (environment, socioe...
Learning Objectives: 1. To provide an overview of relevant hereditary cancer syndromes 2. To encourage providers to obtain a thorough family history 3. To educate providers about available r...
Follow
